阿迪波龙 (AdipoRon) 是阿迪波涅克丁受体激活剂,可以恢复PCOS相关的NAFLD肝脏时钟基因表达
Shivam Sharma1, Shaheen Wasil Kabeer1, Vinod Kumar1
1Laboratory of Epigenetics and Diseases, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S. Nagar, Punjab, 160062, India.
Scientific reports
|September 30, 2025
概括
新型治疗药物阿迪波龙有效治疗与多囊卵巢综合征 (PCOS) 相关的非酒精性脂肪性肝病 (NAFLD),通过减少肝脂肪,改善胰岛素抵抗力和恢复激素平衡. 它还纠正了与疾病相关的表观遗传变化和昼夜基因表达.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 多囊性卵巢综合征 (PCOS) 中的低平素水平与高雄性和非酒精性脂肪肝疾病 (NAFLD) 相相关.
- 与PCOS相关的NAFLD呈现复杂的代谢和荷尔蒙失调,包括胰岛素抵抗和肝脏基因表达的改变.
研究的目的:
- 在NAFLD的体内PCOS大鼠模型中,研究小分子胺素受体激活剂AdipoRon的治疗疗效.
- 阐明AdipoRon作用背后的机制,重点关注代谢,荷尔蒙和表观遗传修饰.
主要方法:
- 使用一种体内PCOS大鼠模型,该模型表现出高雄性和肝硬化.
- 服用阿迪波,并评估其对脂质积累,胰岛素耐药性,脂质生成,高雄性和皮质素水平的影响.
- 分析了使用ChIP试验的肝脏昼夜基因表达 (Bmal1,Clock,Per3,Cry2,Reverba,Rora) 和表观遗传修饰 (H3K4me3,H3K9/14ac,H3K36me2).
主要成果:
- 通过改善胰岛素抵抗和脂质生成,AdipoRon显著降低了肝脏中的脂质积累.
- 在PCOS大鼠中,用AdipoRon治疗逆转了高雄性质和正常化了阿迪波内克缺乏症.
- 阿迪波恢复了改变的肝脏昼夜基因表达,并改善了PCOS诱导的表观遗传变化,包括在特定基因促进者中调节H3K36二甲基化.
结论:
- 通过解决关键的病理特征,阿迪波龙证明了PCOS相关的NAFLD的显著治疗潜力.
- 药物的有效性与其改善代谢参数,纠正荷尔蒙失衡和调节昼夜基因表观遗传调节的能力有关.
- 这些发现凸显了阿迪波作为PCOS-NAFLD临床干预的有希望的候选人,这对了解代谢疾病中的表观遗传机制有意义.
更多相关视频
09:20An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
4.2K
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
2.8K
相关概念视频
02:19Circadian Rhythms and Gene Regulation
4.5K
The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent...
4.5K
01:24Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848